ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing

“In our in vitro model of rat cardiomyocytes, pre-treatment with PKX-001 substantially increased cell survival under stress conditions (exposure to the lipotoxic fatty acid, palmitate and the anthracycline class of drug, doxorubicin). The mechanism of PKX-001 protective activity may in part be explained by its inhibitory effect on cysteine-type endopeptidase activity involved in the apoptotic signaling pathway. PKX-001 had no cytotoxic effect and minimally affected survival and normal functional activity of cardiomyocytes, both in vitro and ex vivo.” - Prof. Dr. Thomas Pulinilkunnil, Ph.D.

PKX-001 is the designation given to the lead drug product molecule of the AAGP® family.

This study is being led by Prof. Dr. Thomas Pulinilkunnil, Ph.D., Diabetes Canada Scholar, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University, Adjunct Professor, University of New Brunswick, Affiliate Scientist, Saint John Regional Hospital, Dalhousie Medicine New Brunswick (DMNB).

Dr. Thomas Pulinilkunnil Bio

According to market research published by iHealthcareAnalyst, the global market for organ transplantation estimated to reach $51 billion by 2025, growing at a CAGR of 9.9% over the forecast period, driven by increasing incidence of organ failures, and rising demand for transplant products such as tissue products, immunosuppressants, and organ preservation solutions.

See the promising research of AAGP® and results to date

Visit our new website at ProtoKinetix.com for more information and to join our email list.

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200814005050/en/